Beta Bionics, Inc.
BBNXNASDAQHealthcare● Active
$13.87
$-0.02(-0.14%)
Market Cap$618070710
P/E Ratio—
52W High$32.71
52W Low$8.8
Beta Bionics, Inc.（BBNX）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · BBNX · 截至 2026-06-08
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 |
|---|---|---|---|---|
| Revenue | ||||
| Revenue | $0.10B | $0.07B | $0.01B | $0.00B |
| Cost of Revenue | $0.04B | $0.03B | $0.01B | $0.00B |
| Gross Profit | $0.06B | $0.04B | $0.01B | $0.00B |
| Gross Margin %(computed) | 55.40% | 55.11% | 52.59% | 100.00% |
| Operating Expenses | ||||
| R&D Expenses | $0.03B | $0.03B | $0.02B | $0.03B |
| G&A Expenses | $0.03B | $0.02B | $0.01B | $0.02B |
| Total Operating Expenses | $0.13B | $0.08B | $0.04B | $0.07B |
| Operating Income | ($0.07B) | ($0.05B) | ($0.04B) | ($0.07B) |
| Operating Margin %(computed) | -71.50% | -69.48% | -298.87% | — |
| Interest Income | $0.01B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.07B) | ($0.05B) | ($0.04B) | ($0.06B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.07B) | ($0.05B) | ($0.04B) | ($0.06B) |
| Net Margin %(computed) | -73.02% | -84.08% | -367.64% | — |
| Per Share & EBITDA | ||||
| EPS (Basic) | $-1.81 | $-8.60 | $-8.31 | $-12.96 |
| Wtd Avg Shares | 0.04B | 0.01B | 0.01B | 0.00B |
| EBITDA | ($0.07B) | ($0.04B) | ($0.03B) | ($0.06B) |
| EBITDA Margin %(computed) | -73.02% | -67.72% | -288.65% | — |
数据来源：Financial Modeling Prep · 最后更新：2026-06-08 · USD · B
深入了解Beta Bionics, Inc.
关于Beta Bionics, Inc.（BBNX）损益表
Beta Bionics, Inc.（BBNX）损益表数据来源于SEC Form 10-K及10-Q申报文件。2025财年，BBNX实现营收$0.10B，毛利润$0.06B（毛利率55.40%），净利润($0.07B)（净利率-73.02%）。
常见问题
BBNX · 4 问Beta Bionics, Inc.（BBNX）2025财年营收为$0.10B，同比up53.9%。
BBNX revenueBBNX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08